Stock report · Delisted · Nasdaq
Vyne Therapeutics Inc (VYNE)
0.02USD Delisted Final close · Jul 17, 2026
VYNE no longer trades. Vyne Therapeutics was delisted from the Nasdaq in July 2026.
All prices on this page are historical. The last trade was on July 17, 2026, at $0.02.
VYNE stock price history
Final trading statistics
- Final close
- $0.02
- Final trading day
- Jul 17, 2026
- Market cap at delisting
- $19.07M
- Shares outstanding
- 0.67M
- Final 52-week range
- $0.00 – $0.02
- Avg. volume (final 3 mo.)
- 562,845
- All-time high
- $1.21 · Dec 2022
- All-time low
- $0.00 · Oct 2018
- Return since IPO
- +6495.4%
- Beta
- 2.01
- Book value / share
- $36.93
- Price / book
- 0.00
About Vyne Therapeutics Inc
VYNE Therapeutics Inc. was a clinical-stage biopharmaceutical company working on treatments for chronic inflammatory and immune-mediated diseases. Its lead program, repibresib gel (VYN201), was a topical small molecule pan-BET inhibitor soft drug designed to act on many inflammatory pathways while limiting exposure in the rest of the body.
It also developed VYN202, an oral BD2-selective BET inhibitor in a Phase 1b trial for short- and long-term control of immune-mediated inflammation. Founded in 2003 and based in Stewartsville, New Jersey, it was called Menlo Therapeutics Inc. until September 2020.
The stock was delisted from the Nasdaq in July 2026, with a final trade on July 17, 2026 at $0.02.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Stewartsville, NJ
- Employees
- 10
- IPO date
- January 25, 2018
- Delisted
- July 17, 2026
- SEC CIK
- 1566044
Vyne Therapeutics financials before the delisting
The last 5 fiscal years Vyne Therapeutics reported as a public company, fiscal year ending December.
VYNE revenue and net income
VYNE earnings per share
VYNE annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $570.0K | −$26.5M | −$30.50 |
| FY2024 | $501.0K | −$39.8M | −$25.93 |
| FY2023 | $424.0K | −$28.5M | −$352.00 |
| FY2022 | $477.0K | −$23.2M | −$248.85 |
| FY2021 | $931.0K | −$73.3M | −$1152.54 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Vyne Therapeutics stock FAQ
What happened to Vyne Therapeutics stock?
Vyne Therapeutics was delisted from the Nasdaq in July 2026. The final close was $0.02 on July 17, 2026.
Can I still buy VYNE stock?
No. VYNE is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on July 17, 2026.
What was the last price of VYNE?
VYNE last closed at $0.02 on July 17, 2026, which valued the company at about $19.07M.
How did Vyne Therapeutics do in its last full fiscal year?
In fiscal 2025, its last full year as a public company, Vyne Therapeutics reported revenue of $570.0K and net income of −$26.5M.
When did Vyne Therapeutics go public?
Vyne Therapeutics shares started trading on January 25, 2018.
VYNE no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.